Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

Groundbreaking research on brain receptors could yield better treatments for Schizophrenia & Parkinson's

Yale University : 02 March, 2000  (New Product)
Yale research on the new protein Calcyon could lead to development of more effective drugs for conditions which are marked by dopamine deficiency, such as Parkinson's, chronic schizophrenia and possibly attention deficit hyperactivity disorder.
Yale research on the new protein Calcyon could lead to development of more effective drugs for conditions which are marked by dopamine deficiency, such as Parkinson's, chronic schizophrenia and possibly attention deficit hyperactivity disorder.

Researchers at Yale and Medical College of Georgia have identified proteins in the dopamine signaling pathway, which interact with the D1 receptor, one of five known dopamine receptors. Published in the March 3 issue of Science, the paper describes how a novel protein called Calcyon (for calcium 'on') interacts with the D1 receptor to enhance release of calcium within the cell, thereby increasing dopamine's actions.

'The D1 receptor is prominent in prefrontal cortical neurons that carry out memory functions and we found that Calcyon is also present in the same cells,' said Patricia Goldman-Rakic, professor of neurobiology, neurology and psychiatry at Yale School of Medicine. 'The next step is to learn if Calcyon can increase the response of these neurons in the living animal.'

This work, Goldman-Rakic said, reveals a new pathway for D1 signaling and it opens up the possibility that Calcyon may be a new target for drug development aimed at improving the signaling in cells which are otherwise desensitized to dopamine. This is particularly important because most of the drugs now used in those disorders have negative consequences after long term use.

The team's studies have now shown that memory impairments produced by loss of D1 stimulation can be reversed by the application of an experimental drug which stimulates the D1 receptor specifically.

'We've seen only positive results in laboratory trials,' Goldman-Rakic said. 'The time is right for clinical trials with drugs containing D1 agonist properties.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo